All In MedTech

Device Trial Radar · NCT03942367

Evaluation of the Safety and Effectiveness of the vPatch Device

Evaluation of the Safety and Effectiveness of the vPatch Device for the Management and Treatment of Premature Ejaculation

Last checked: Nov 20, 2026Latest source record: Oct 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Sep 10, 2019

Primary completion

Jul 15, 2020

Study completion Jul 16, 2020

Sponsor

Lead sponsor
Virility Medical Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Sintesi Research Srl
First posted
May 8, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Multi-center, international, prospective, randomized, double-blind, two-arms, sham-controlled, first-in-human clinical investigation. The Patients will be allocated to one of the following groups: * Group A (Active Device Group): Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient. * Group B (Sham Device Group): Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient. The study will start with a Screening Visit (Visit 1), when potential Patients complaining of PE will be informed about the investigation and its objectives. If they agree to participate, after signing a valid Informed Consent Form they will undergo a full medical history and physical examination and will be selected according to eligibility criteria except IELT (which will be examined at the next visit). The primary objective of this study is to assess the safety profile of the vPatch device and its effectiveness in delaying ejaculation when used in Patients suffering of PE. The secondary objectives of this study are: * To assess the Patient's perception of the ease of use of the vPatch device and treatment, through the use of a dedicated questionnaire (Usability Questionnaire). * To assess the Patient's perception of the changes in his Premature Ejaculation Profile (PEP) under different aspects with the use of device, through the use of a dedicated questionnaire (Control and Distress Domains of the Premature Ejaculation Profile (PEP) Questionnaire). * To assess the Patient's perceived intensity of orgasm by using the vPatch device, through the use of a validated tool (Orgasmometer).

Conditions

  • Premature Ejaculation

Interventions

  • Active Device (vPatch)Device

    Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.

  • Sham Device (vPatch)Device

    Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events rate during the study period. All adverse occurrences (serious/non-serious or device-related/non device-related) will be recorded prospectively, categorized and evaluated for causality using defined criteria.Time frame: Entire Study Period (up to 2,5 months)
  2. Objective: change in IELT from baseline (V2) to the end of Home Phase Visit (V3).Time frame: Up to 56 days
  3. Subjective: proportion of patients reporting an improvement according to the Clinical Global Impression of Change (CGIC) measured at V3.Time frame: Up to 56 days

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Sexual Dysfunction Clinic, Rambam Medical Center

    Haifa, Israel

  • U.O.C. Urologia e Centro di litotrissia urinaria D.A.I. Nefrologia, urologia e chirurgia generale e dei trapianti di rene, anestesia e rianimazione, A.O.U. "Federico II" di Napoli

    Naples, Italy

  • Urologia, Casa di Cura "Villa Donatello"

    Sesto Fiorentino, Firenze, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.